Broege, A.; Rossetti, S.; Sen, A.; Menon, A.S.; MacNeil, I.; Molden, J.; Laing, L.
Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib. Cancers 2024, 16, 3520.
https://doi.org/10.3390/cancers16203520
AMA Style
Broege A, Rossetti S, Sen A, Menon AS, MacNeil I, Molden J, Laing L.
Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib. Cancers. 2024; 16(20):3520.
https://doi.org/10.3390/cancers16203520
Chicago/Turabian Style
Broege, Aaron, Stefano Rossetti, Adrish Sen, Arul S. Menon, Ian MacNeil, Jhomary Molden, and Lance Laing.
2024. "Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib" Cancers 16, no. 20: 3520.
https://doi.org/10.3390/cancers16203520
APA Style
Broege, A., Rossetti, S., Sen, A., Menon, A. S., MacNeil, I., Molden, J., & Laing, L.
(2024). Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib. Cancers, 16(20), 3520.
https://doi.org/10.3390/cancers16203520
